Management of Localized Prostate Cancer by Focal Transurethral Resection of Prostate Cancer : An Application of Radical TUR-PCa to Focal Therapy

الملخص EN

Background.

We analyzed radical TUR-PCa against localized prostate cancer.

Patients and Methods.

Seventy-nine out of 209 patients with prostate cancer in one lobe were studied.

Patients’ age ranged from 58 to 91 years and preoperative PSA, 0.70 to 17.30 ng/mL.

In other 16 additional patients we performed focal TUR-PCa.

Patients’ age ranged from 51 to 87 years and preoperative PSA, 1.51 to 25.74 ng/mL.

Results.

PSA failure in radical TUR-PCa was 5.1% during the mean follow-up period of 58.9 months.

The actuarial biochemical non-recurrence rate was 98.2% for pT2a and 90.5% for pT2b.

Bladder neck contracture occurred in 28 patients (35.4%).

In 209 patients, pathological study revealed prostate cancer of the peripheral zone near the neurovascular bundle bilaterally in 25%, unilaterally in 39% and no cancer bilaterally in 35%, suggesting the possibility of focal TUR-PCa.

Postoperative PSA of 16 patients treated by focal TUR-PCa was stable between 0.007 and 0.406 ng/mL at 24.2 months’ follow-up.

No patients suffered from urinary incontinence.

Bladder neck contracture developed in only 1 patient and all 5 patients underwent nerve-preserving TUR-PCa did not show erectile dysfunction.

Conclusion.

Focal TUR-PCa was considered to be a promising option among focal therapies against localized prostate cancer.